Crinetics Pharmaceuticals, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
84.84 ^USD	-0.01%		+0.18%	+82.26%

08-28	Crinetics Pharmaceuticals, Inc. - Shareholder/Analyst Call
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT

Published on 08/28/2026 at 12:50 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Special Meeting of Shareholders of Crinetics Pharmaceuticals. The shareholder meeting will begin now and will be

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

08-28	Crinetics Pharmaceuticals, Inc. - Shareholder/Analyst Call
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-03	Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M	MT
08-03	Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	Vertex raises annual revenue forecast on cystic fibrosis drugs strength	RE
07-28	UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55	MT
07-08	Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says	MT
07-07	IBT company Crinetics to be acquired by Vertex for USD10 billion	AN
07-07	Top Midday Gainers	MT
07-07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07-07	Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network	MT
07-07	SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Soars on Buyout \| Stock Movers	MT
07-07	Global markets live: Broadcom, Meta, Walmart, Intel, AbbVie…
07-07	LifeSci Capital Downgrades Crinetics Pharmaceuticals to Market Perform From Outperform, Price Target is $85	MT
07-07	Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics -- Market Talk	DJ